Alem dos efeitos classicos relacionados ao estimulo a eritropoiese, os estudos tem demonstrado que a administracao subcutanea de rHuEPO
, em diferentes doses, pode potencializar a capacidade aerobia de humanos (Audran e colaboradores, 1999; Juel e colaboradores, 2007), explicada principalmente pelo aumento da oferta de [O.sub.2] para os musculos ativos.
The purpose of our experiments was to investigate the pharmacokinetics of PEGvlated rHuEPO
(PEG-rHuEPO) with remarkably large molecular weight in rats.
These can be useful parameters to establish recent reticulocyte stimulation of reticulocytes in response to rHuEpo
usage contrasting with results seen in normal physiologic RBC production.
To fulfil the high medical demand for Epo globally, large scale production of recombinant Human Epo (rHuEpo
) was originally initiated in Chinese Hamster Ovary (CHO) cells (1).
Rekombinan erythropoietin (rHuEPO
) ile transfuzyon ihtiyaci azaldi.
As a result, NESP(R) has the advantage of less frequent administration as compared with conventional rHuEPO
preparations, and excellent efficacy in the treatment of anemia.
Since the late 1980s, blood doping has been achieved through the administration of rHuEPO
is a genetically engineered protein, structurally almost identical to the naturally occurring erythropoietin, which is produced by the kidneys to stimulate red cell production.
enhances athletic performance by increasing the number of erythrocytes (4).
This anemia can, in part, be reversed with the use of recombinant human erythropoietin (rhuEPO
Current pediatric nephrology practice recommends the use of synthetic recombinant human erythropoietin (rHuEpo
) and recombinant human growth hormone (rHuGH), beginning early in the course of renal failure treatment and continuing to end stage (Muirhead et al., 1995; NAPRTCS, 1995).
To examine health resource utilization and associated costs among the Medicaid ESRD study population, health care services were grouped into 1 of 10 categories: (1) inpatient hospital services; (2) outpatient dialysis services (see Technical Note); (3) outpatient physician services; (4) outpatient laboratory services; (5) recombinant human erythropoietin rHuEPO
) services (extracted from outpatient hospital services for Michigan and from other outpatient services for California and Georgia); (6) outpatient hospital and other services (including transportation to and from dialysis and emergency room services); (7) home health care services; (8) nursing home services; (9) intermediate care facility services; and (10) pharmacy services.
 studied the effect of improvement in anemia on event-related potentials (ERPs)-P300; in chronic kidney disease after administration of recombinant human erythropoietin (rhuEPO